ClinicalTrials.gg
TerminatedNCT05242510DESDEEUpdated Apr 4, 2025

Evaluation of Exotropia After Patching the Eye or After Prism Adaptation

An interventional study of Patching and Prism Adaptation in Exotropia, sponsored by University of Rochester. Terminated at 9 sites in 5 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by University of Rochester · Not applicable, Interventional, and Treatment

Why this study was terminated
lack of ability to enroll from other sites
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Study summary

This study intends to determine the number and percent of subjects initially diagnosed with divergence excess exotropia which would be reclassified as simulated divergence excess exotropia if tested after 24 hours of monocular occlusion (patching) or after prism adaptation for the distance angle.

02

Conditions studied

  • Exotropia

Browse trials for

03

In context

Exotropia

58 studies on the registry are indexed under Exotropia; 13 are open to participants now.

This study's enrollment of 1 is below the median of 50 across 49 interventional studies indexed under Exotropia.

Browse Exotropia studies →

Lead sponsor

University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with divergence excess exotropia according to standard criteria (see Study Procedures for specifics)
  • No prior strabismus surgery
  • Able to cooperate with testing (by examiner determination)
  • Neurologically normal except for strabismus (ADHD and autism spectrum are not exclusion criteria as long as the subject can cooperate for necessary testing)
  • Not amblyopic at the time of enrollment (best-corrected visual acuity in both eyes of 20/40 or better)
  • Under 18 years of age. There is no lower age limit as long as the subject can cooperate for the required testing.
  • No diagnosis of dissociated vertical deviation

Exclusion criteria

Exclusion Criteria:

  • No diagnosis of divergence excess exotropia according to standard criteria (see Study Procedures for specifics)
  • Prior strabismus surgery
  • Unable to cooperate with testing (by examiner determination)
  • Diagnosed with a neurological disorder (ADHD and autism spectrum are not exclusion criteria as long as the subject can cooperate for necessary testing)
  • Best-corrected visual acuity in either eye worse than 20/40
  • 18 years of age or older
  • Diagnosed with dissociated vertical deviation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Patching

    Procedure: Patching

  • Experimental
    Prism Adaptation

    Procedure: Prism Adaptation

Interventions

  • ProcedurePatching

    The subject will occlude the non-dominant eye for 24 hours.

  • ProcedurePrism Adaptation

    The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.

06

What researchers measure

Primary outcomes

  1. Percent of participants reclassified as divergence excess exotropia

    Percentage of patients with distance and near exotropia measurements within 2.5 prism diopters on alternate prism and cover testing after 24 hours of patching or 7-14 days of fresnel prism use.

    Time frame: 2 weeks

  2. Percent of participants reclassified as simulated divergence excess exotropia

    Percentage of patients with distance and near exotropia measurements differing by more than 2.5 prism diopters on alternate prism and cover testing after 24 hours of patching or 7-14 days of fresnel prism use.

    Time frame: 2 weeks

07

Study locations

9 sites
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Harvard University
    Boston, Massachusetts 02115, United States
  • Ross Eye Institute
    Buffalo, New York 14209, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Queen's University
    Kingston, Ontario, Canada
  • LV Prasad Eye Institute
    Hyderabad, India
  • Shamir Medical Center
    Rishon LeZion, Central, Israel
  • University of Milan
    Milan, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05242510
Responsible party
Matthew Gearinger (Professor, University of Rochester) — Principal investigator
First posted
Feb 16, 2022
Start date
Aug 27, 2024
Primary completion
Sep 18, 2024
Completion
Sep 18, 2024
Last update
Apr 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion